Mendeley  

Zotero  

Nasri P, Sadeghi S, Hovsepian S, Chegini R, Soltani Esmaeili S, Kiani G. COVID-19 in Children With Inflammatory Bowel Disease: A Systematic Review. J. Pediatr. Rev 2022; 10 (4) :277-286
URL: http://jpr.mazums.ac.ir/article-1-476-fa.html

Background: Considering the chronic immunosuppression in inflammatory bowel disease (IBD) patients, it is necessary to evaluate the course of COVID-19 in these patients. Studies have shown various results in adult IBD patients. This study aimed to find out the course of this infection in pediatric IBD patients. 
Methods: This was a systematic review study according to the PRISMA 2020 guideline. International databases including Scopus, PubMed, and the Web of Science were searched with a combination of “COVID-19” AND “IBD” or synonyms until October 16, 2021. Studies that have reported the outcomes of COVID-19 infection in patients less than 19 years of age were selected. Name of author, country, study duration and type, IBD type and drugs, and COVID-19 outcomes were extracted.
Results: From the initially retrieved 2215 articles, finally 16 articles were eligible. Data from 1040 pediatric IBD patients were reported. Twenty-four patients were hospitalized, 5 developed patients multisystem inflammatory syndrome in children, and others had a mild disease course and were outpatient. Steroid use, severe IBD activity, and comorbidities were shown to increase risk of hospitalization and disease severity.
Conclusion: COVID-19 is a benign and self-limited disease in pediatric IBD patients. Comorbidities, steroid use, and severe IBD activity affect the outcomes.